Aisling Barrett
@ABarrettHaem
Followers
256
Following
650
Media
19
Statuses
117
Doctoral candidate @UniOfOxford UK Hodgkin Lymphoma subgroup ECR @UKECRC @EHA_Hematology CRTH scholar @ECMC_UK JING Steering Group Member @tcddublin alumnus
Joined May 2021
Having learned every @BritSocHaem guideline off by heart for my FRCPath, it was very exciting to have been afforded the opportunity to lead an amazing group of co-authors for our GPP regarding bleomycin use in Hodgkin Lymphoma- published today!.
onlinelibrary.wiley.com
Recommendations from the British Society of Haematology regarding bleomycin pulmonary toxicity (BPT) in classical Hodgkin lymphoma (CHL) centre around (1) appropriate patient selection, (2) routine...
2
15
54
RT @graham74GC: It’s back and it’s online. The fantastic #lymphomaManagement course. With much thanks to @LymphomaAction for their suppor….
0
7
0
4
6
26
RT @vit_prochazka: Two important posters on elderly CHLs! 🇪🇸and especially 🇬🇧 shows vital role of anthracyclines! Know and Protect ❤️🩹at a….
0
1
0
RT @graham74GC: Great work by @ABarrettHaem. NHSE data, older #Hodgkin pts. Outcomes ⬆️ with dox. Clearly may reflect selection, but intere….
0
4
0
RT @DrRaulCordoba: Huge interest in older patients 👵👴 with #Hodgkin #Lymphoma at #18ICML #icml2025. Don’t miss posters P365 by @ABarrettHae….
0
5
0
RT @EHA_Hematology: Applications are ongoing for our 2026 Clinical Research Training in Hematology (#CRTH) program. This unique, nine-month….
0
6
0
If you’re at #ICML2025 come by my poster 1230-1300. We examine survival by anthracycline use in older cHL patients. TLDR: use anthracycline if at all possible! @DavidJCutter @graham74GC
2
9
44
RT @vit_prochazka: Heading to #icml25 by the train called A Einstein. There’s no way this is just a coincidence! Looking forward to meeting….
0
1
0
Obligatory #CRTH selfie at the @EHA_Hematology Presidential Reception, in such a beautiful setting overlooking the #Duomo
0
2
33
RT @DrRaulCordoba: #Hematology Clonal relatedness as a prognostic marker in #Richter transformation of chronic lymphocytic leukemia #CLL: a….
ashpublications.org
Abstract. The disease shift of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL), so-called Richter transformation (RT), is a cat
0
8
0
RT @DrRaulCordoba: #CRTH is not only #hematology but #collaboration, #mentorship and #networking. #CRTH is #BorderlessHematology in @EHA_He….
0
5
0
RT @vit_prochazka: Love to chair @EHA_Hematology CRTH promoting workshop for young scientists! Great on-hand experience of @ABarrettHaem @t….
0
3
0
Thank you so much for the invitation to speak on our NHS registry analysis @DavidJCutter and looking forward to further collaboration with the Czech Hodgkin Study Group on the HoOP study @graham74GC exciting things to come!.
Insightful presentation on Elderly Hodgkins in the UK by @ABarrettHaem at the 🇨🇿Annual Hematology Congress, big kudos! Proud to collaborate on 🇬🇧🇪🇺HoOP project 🤝! Very important field of study! @EHA_Hematology
0
0
9
RT @DrRaulCordoba: @ABarrettHaem, @EHA_Hematology #CRTH 2025 scholar, to present the ASSOCIATION BETWEEN ANTHRACYCLINE USE AND CLINICAL OUT….
0
1
0
Great to see UK pivotal MCL data (ENRICH) being presented at Olomoucké Hematologické Dny by Dr Klener. A practice changing study 👏
0
0
4
Very nice to explore Olomouc this morning and looking forward to speaking later at the Olomoucké Hematologické Dny. Kudos to @vit_prochazka for his excellent hosting of this wonderful meeting!
1
0
10
RT @graham74GC: Great news - NICE have approved AVD-BV for 1L treatment of advanced stage Hodgkin Lymphoma. Great to have an additional opt….
nice.org.uk
0
18
0
RT @tobyeyre82: Where do we stand re the evidence for clonality testing in Richter transformation of #CLL? . Clonal relatedness as a progn….
ashpublications.org
Abstract. The disease shift of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL), so-called Richter transformation (RT), is a cat
0
7
0
- Up to 50% failure of assay in studies: we must have contingency for test failure. - Does not seem to be as important in novel therapy era (MOLTO, BRUIN: no effect on ORR). - Must be embedded into prospective clinical trials!.
0
0
1